| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-16 号 | | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | 奥佳华智能健康科技集团股份有限公司 第六届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）第六届监事会 第七次会议通知以电话、传真及电子邮件等方式于 2025 年 4 月 17 日发出。会议 于 2025 年 4 月 27 日上午 11:00 在厦门市湖里区安岭二路 31-37 号公司八楼会议 室以现场方式召开，并获得全体监事确认。本次会议应到监事 3 名，实际出席会 议监事 3 名。本次会议由公司监事会主席杨青女士主持，会议符合《中华人民共 和国公司法》和公司章程的有关规定。 经全体监事认真审议，以现场表决方式通过了如下决议： 一、会议以 3 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2024 年度监事会工作报告的议案》，本议案需提交 2024 年年度股东大会审议。 二、会议以 3 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-04 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 根据立信会计师事务所（特殊普通合伙）审计结果，2024 年度公司实现营 业收入 483,332.19 万元，同比下降 3.92%；归属于上市公司股东的净利润 6,423.87 万元，同比下降 37.76%。 二、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2024 年度募集资金存放与使用情况的专项报告的议案》。 本议案已经公司董事会审计委员会审议通过。 三、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2024 年度内部控制自我评价报告的议案》。 本议案已经公司董事会审计委员会审议通过。 四、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2024 年度利润分配预案的议案》，本议案需提交公司 2024 年年度股东大会审议。 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-07 号 | | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | 奥佳华智能健康科技集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 若在利润分配预案公布后至实施前，公司总股本发生变动的，则以未来实施 利润分配方案时股权登记日的总股本为基数，按照分配比例不变的原则对分配总 额进行调整。 上述利润分配方案将于股东大会审议通过之日起两个月内实施完毕。 1/ 3 3、如本项议案最终获得股东大会审议通过，公司 2024 年度现金分红总额预 计为 62,347,675.20 元（含税），占公司 2024 年度归属于上市公司股东净利润的 97.06%。 二、现金分红方案的具体情况 （一）公司 2024 年度利润分配预案未触及其他风险警示情形 1、最近三个会计年度利润分配情况： 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开了第六届董事会第八次会议及第六 ...

Financial Performance - The company's revenue for Q1 2025 was ¥1,147,544,843.46, representing a year-over-year increase of 9.17% compared to ¥1,051,117,744.65 in the same period last year[5]. - Net profit attributable to shareholders decreased by 60.04% to ¥1,997,005.34 from ¥4,996,914.97 in the previous year[5]. - The company reported a basic earnings per share of ¥0.003, down 70.00% from ¥0.01 in the same period last year[5]. - Net profit for the current period was ¥1,721,942.79, a decrease of 66.19% from ¥5,103,538.76 in the previous period[25]. - Total operating revenue for the current period reached ¥1,147,544,843.46, an increase of 9.15% compared to ¥1,051,117,744.65 in the previous period[24]. - Total operating costs amounted to ¥1,145,349,011.63, up from ¥1,060,968,546.72, reflecting a rise of 7.97%[24]. - Total comprehensive income for the current period was ¥14,133,831.65, a significant increase from ¥88,551.05 in the previous period[26]. Cash Flow and Investments - The net cash flow from operating activities improved by 49.46%, reaching -¥93,972,745.38, compared to -¥185,951,326.25 in Q1 2024[5]. - Cash flow from operating activities showed a net outflow of ¥93,972,745.38, an improvement from a net outflow of ¥185,951,326.25 in the previous period[28]. - The company generated ¥1,290,124,316.00 in cash inflows from operating activities, compared to ¥1,155,022,311.60 previously, indicating a growth of 11.65%[27]. - The net cash flow from investing activities decreased by 41.95% to ¥98,738,649.97 compared to ¥170,091,100.29 in Q1 2024[14]. - The net cash flow from investing activities was ¥98,738,649.97, down from ¥170,091,100.29, reflecting a decrease of 42.00%[28]. Assets and Liabilities - The total assets as of March 31, 2025, were ¥7,386,058,803.08, a decrease of 2.57% from ¥7,581,151,714.95 at the end of the previous year[5]. - The company’s total liabilities increased significantly, with current liabilities due within one year rising by 263.73% to ¥578,655,982.47[9]. - Total liabilities decreased to ¥2,903,222,418.51 from ¥3,114,262,583.57, a reduction of about 6.8%[22]. - Total current assets decreased to ¥3,988,725,331.88 from ¥4,205,465,727.75, a decline of approximately 5.2%[20]. - The company’s cash and cash equivalents decreased to ¥670,709,325.85 from ¥799,276,742.37, a decline of approximately 16.1%[20]. - The company reported a total asset decrease to ¥7,386,058,803.08 from ¥7,581,151,714.95, a decline of about 2.6%[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 44,531[16]. - The largest shareholder, Zou Jianhan, holds 20.47% of shares, totaling 127,620,000 shares, with 32,000,000 shares pledged[16]. - The number of shares held by the top 10 shareholders represents a significant concentration of ownership, with the top two shareholders holding a combined 38.50%[16]. Other Information - The company experienced a significant increase in receivables financing, which rose by 9809.42% to ¥27,232,674.99 from ¥274,816.00[9]. - The company reported a decrease in financial expenses by 233.69%, resulting in a financial income of -¥20,755,256.40 compared to ¥15,524,364.16 in the previous year[12]. - The company’s investment income decreased by 67.07% to ¥7,180,767.12 from ¥21,805,060.20 in the previous year[12]. - The company has not reported any new product developments or market expansion strategies in the current conference call[18]. - The company reported a significant increase in interest income, which rose to ¥10,537,101.54 from ¥2,675,485.60, marking a growth of 293.36%[25].

Financial Performance - The company's operating revenue for 2024 was ¥4,833,321,898.13, a decrease of 3.92% compared to ¥5,030,460,330.75 in 2023[19] - The net profit attributable to shareholders for 2024 was ¥64,238,678.27, down 37.76% from ¥103,203,187.17 in 2023[19] - The net cash flow from operating activities significantly dropped by 85.45% to ¥130,209,055.41 from ¥895,115,094.07 in the previous year[19] - Basic earnings per share for 2024 were ¥0.10, a decline of 41.18% compared to ¥0.17 in 2023[19] - Total assets at the end of 2024 were ¥7,581,151,714.95, reflecting a decrease of 5.47% from ¥8,019,424,770.29 at the end of 2023[19] - The net assets attributable to shareholders decreased by 3.19% to ¥4,433,152,870.49 from ¥4,579,259,999.09 in 2023[19] - The weighted average return on net assets for 2024 was 1.43%, down from 2.24% in 2023[19] - The net profit after deducting non-recurring gains and losses was ¥24,348,249.49, a decrease of 20.88% from ¥30,774,523.87 in 2023[19] Revenue Breakdown - The main business revenue accounted for ¥4.68 billion, representing 96.79% of total revenue, down 4.73% from ¥4.91 billion in 2023[55] - Health massage products generated ¥3.72 billion, which is 79.59% of main business revenue, showing a slight increase of 0.60% from ¥3.70 billion in 2023[56] - The sales of massage chairs reached ¥2.05 billion, making up 43.75% of main business revenue, a decline of 5.34% from ¥2.16 billion in 2023[55] - The revenue from massage small appliances increased by 8.96% to ¥1.68 billion, representing 35.84% of main business revenue[56] - Domestic sales were approximately ¥1.44 billion, accounting for 30.75% of total revenue, down 5.70% from ¥1.53 billion in 2023[56] - International sales were about ¥3.24 billion, making up 69.25% of total revenue, a decrease of 4.30% from ¥3.39 billion in 2023[56] Market Expansion and Product Development - The company achieved over 50% revenue contribution from its own brand during the reporting period, emphasizing its focus on the health industry and autonomous brand development[28] - The flagship massage chair OG-9598 was launched, featuring a pioneering 5D massage mechanism and AI algorithms, achieving high sales despite its premium price[29] - The company expanded its offline market presence by entering new growth channels such as Sam's Club and Costco, enhancing its competitive position[30] - The brand's net profit increased by 106.89% year-over-year, indicating a significant improvement in profitability during the reporting period[30] - The company is actively exploring new markets along the Belt and Road Initiative, successfully entering multiple countries[28] - The introduction of new products in the mid-range and high-value segments has strengthened the company's competitive edge in the market[29] Research and Development - The company invested 232 million yuan in R&D during the reporting period, focusing on AI algorithms and health detection software[34] - The company has accumulated 2,292 authorized patents, with 1,340 being valid, indicating strong innovation capabilities[34] - The company is focusing on enhancing its "AI + massage" strategy, integrating advanced technologies for personalized health management services[52] - The number of R&D personnel increased by 4.16% to 827, with the proportion of R&D personnel in the total workforce rising to 9.76%[67] Cash Flow and Financial Management - Operating cash inflow decreased by 15.82% to ¥4,760,712,027.04, while operating cash outflow decreased by 2.72% to ¥4,630,502,971.63, resulting in a net cash flow of ¥130,209,055.41, down 85.45% year-on-year[68] - Investment cash inflow surged by 675.57% to ¥1,655,164,383.18, while investment cash outflow increased by 121.83% to ¥1,263,755,921.05, leading to a net cash flow of ¥391,408,462.13[68] - The company's financial expenses saw a significant increase of 631.97% due to a substantial decrease in foreign exchange gains[66] - The company reported an investment income of ¥67,478,588.43, which constituted 73.87% of the total profit, primarily from foreign exchange settlements and structured deposit returns[70] Corporate Governance and Management - The company has a governance structure that complies with relevant laws and regulations, ensuring independence from its controlling shareholders[111] - The company held its annual general meeting with a 42.99% investor participation rate, approving key financial reports and budget plans[114] - The company has a total of 8 directors, with the chairman holding 127,620,000 shares, representing approximately 52.5% of the total shares held by management[116] - The company has maintained its management team since 2010, with the current term ending in September 2026[116] - The company has a diverse management team with backgrounds in various fields, including finance, engineering, and healthcare[118][120] Environmental Compliance - The company has maintained compliance with environmental protection laws and standards, including the "Environmental Protection Law of the People's Republic of China" and various industry standards[150] - The wastewater treatment facility at the subsidiary, Zhangzhou Mengfali, processes wastewater through pre-treatment and a complete flotation system, with a total discharge of 153,000 tons per year[151] - The company has implemented a self-monitoring plan for environmental compliance, with all monitoring data meeting standards during the reporting period[153] - The company has established an emergency response plan for environmental incidents, enhancing its capability to handle such events[154] Social Responsibility - The brand "OGAWA" received six awards during the International Consumer Rights Day event, including "National Leading Brand in Massage Chair Industry" and "National Quality Assurance Product," reflecting strong consumer recognition[161] - The company donated over RMB 200,000 to support flood relief and community development, including a specific donation of RMB 1 million for cardiac rescue projects at Xiamen University First Affiliated Hospital[163]

Core Viewpoint - The announcement details the issuance and conversion status of the convertible bonds of Aojiahua Intelligent Health Technology Group Co., Ltd, including adjustments to the conversion price and the current status of the company's shares [1][2][3][4][5]. Convertible Bond Issuance - The company issued 12 million convertible bonds with a total value of 1.2 billion RMB, each with a face value of 100 RMB, approved by the China Securities Regulatory Commission [1]. - The bonds were listed and began trading on March 18, 2020, under the name "Aojia Convertible Bonds" with the code "128097" [2]. Conversion Price Adjustments - The conversion price of the bonds has been adjusted multiple times due to cash dividends, with the latest adjustment reducing the price from 9.75 RMB to 9.45 RMB effective from May 29, 2024 [3][4]. Conversion and Share Changes - The conversion period for the bonds is from September 2, 2020, to February 25, 2026 [5]. - As of March 31, 2025, the remaining balance of convertible bonds is approximately 458.27 million RMB (4,582,702 bonds), and the total share capital has increased from 623,476,647 shares to 623,476,752 shares due to the conversion [5].

奥佳华智能健康科技集团股份有限公司 2025 年第一季度可转换公司债券转股情况公告 | 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-03 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 股票代码：002614 股票简称：奥佳华 债券代码：128097 债券简称：奥佳转债 转股价格：人民币 9.45 元/股 转股日期：2020 年 9 月 2 日至 2026 年 2 月 25 日 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）根据《深圳证 券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 15 号— —可转换公司债券》等有关规定，现将 2025 年第一季度可转换公司债券（以下 简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债上市发行情况 （一）可转债发行情况 经中国证券监督管理委员会证监许可【2019】1966 号文核准，公司于 2020 年 2 月 25 日公开发 ...

Core Insights - OgaHua's AI massage robot has successfully integrated with DeepSeek, enhancing user interaction through an OTA update [1] - The company is accelerating its layout to create a health ecosystem AI model aimed at providing comprehensive health services to consumers [1] Group 1: Technology and Innovation - OgaHua focuses on the development and tracking of cutting-edge technologies in the health industry, utilizing AI, IoT, and cloud computing for innovative applications [2] - The AI massage robot features pioneering technologies such as adaptive 5D mechanism, SenseTag system, and full-cycle health management, making massages more precise and personalized [2] - DeepSeek will analyze health data indicators collected by the SenseTag system to provide tailored health recommendations and enhance user experience [2] Group 2: Strategic Development - The health industry is actively exploring deep integration and application of AI, which drives innovation to optimize user experience and service value [3] - OgaHua is building a health ecosystem AI model, ensuring data security while employing a dual approach of cloud computing and private deployment for intelligent health management services [3] - The company is committed to innovation and long-term investment, with projects like the intelligent massage robot based on traditional Chinese medicine theory successfully passing inspections [3]

证券代码： 002614 证券简称：奥佳华 奥佳华智能健康科技集团股份有限公司 投资者关系活动记录表 编号：2025-01 投资者关系活动 类别 √ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 参与单位名称及 人员姓名 诺安基金：张伟民； 华创证券：秦一超、樊翼辰。 时间 2025 年 2 月 21 日（周五）上午 10:00 地点 厦门市湖里区安岭二路 31-37 号 8 楼 上市公司接待人 员姓名 李巧巧、陈艺抒、廖晶、林秋燕、杨文为 投资者关系活动 主要内容介绍 一、投资者参观展厅并体验了核心产品 二、公司整体业务和战略规划概况介绍 三、互动交流摘要 1、公司销售费用占比偏高的原因是什么？另外，销售费用 中的折旧费主要是什么费用？ 公司主要经营包括保健按摩（按摩椅、按摩小电器）、健康 环境（新风系统、空气净化器）等健康产品。为提高产业链自主 可控能力，多年来，全球化自主品牌与 ODM 业务双轮驱动发展， 公司持续在全球多个核心市场进行自主品牌布局与建设，目前旗 下"OGAWA 奥佳华"、"ihoco 轻松伴侣"、"BRI 呼博士"、 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-02 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 2、债权登记日：2025 年 2 月 24 日； 3、除息日：2025 年 2 月 25 日； 4、付息日：2025 年 2 月 25 日； 5、"奥佳转债"票面利率：第一年 0.40%、第二年 0.60%、第三年 1.00%、 第四年 1.50%、第五年 1.80%、第六年 2.00%； 6、"奥佳转债"本次债券付息的债权登记日为 2025 年 2 月 24 日，凡在 2025 年 2 月 24 日（含）前买入并持有本期债券的投资者享有本次派发的利息；2025 年 2 月 24 日卖出本期债券的投资者不享有本次派发的利息。 7、下一付息期起息日：2025 年 2 月 25 日； 8、下一付息期利率：2.00%。 可转换公司债券 2025 年付息公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"奥佳 ...